MCID: INT303
MIFTS: 50

Intracranial Hypertension, Idiopathic

Categories: Rare diseases, Neuronal diseases, Cardiovascular diseases

Aliases & Classifications for Intracranial Hypertension, Idiopathic

MalaCards integrated aliases for Intracranial Hypertension, Idiopathic:

Name: Intracranial Hypertension, Idiopathic 57 53
Pseudotumor Cerebri 57 12 76 53 54 59 55 44 15 73
Idiopathic Intracranial Hypertension 12 53 59
Benign Intracranial Hypertension 12 54 59
Iih 53 59
Benign Intracran. Hypt. 12

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
intracranial hypertension, idiopathic:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

OMIM 57 243200
Disease Ontology 12 DOID:11459
ICD10 33 G93.2
ICD9CM 35 348.2
MeSH 44 D011559
NCIt 50 C85035
Orphanet 59 ORPHA238624
UMLS via Orphanet 74 C0033845
ICD10 via Orphanet 34 G93.2
MedGen 42 C0033845
UMLS 73 C0033845

Summaries for Intracranial Hypertension, Idiopathic

NIH Rare Diseases : 53 Idiopathic intracranial hypertension (IIH), formerly known as pseudotumor cerebri, is a condition that affects the brain. Pseudotumor cerebri literally translates to "false brain tumor." This term was used because symptoms of IIH resemble those of brain tumors depsite no tumor being present. Symptoms of IIH may include severe headache, nausea and vomiting, altered vision, and pulsating sounds within the head. A person with IIH may also have symptoms such as a stiff neck, back or arm pain, eye pain, and memory problems. If the condition remains untreated, permanent visual loss or blindness may develop. While the exact underlying cause of IIH is not known (idiopathic), it is likely due to high fluid pressure within the skull that is due to buildup, or poor absorption, of cerebrospinal fluid (CSF). IIH most often (but not always) occurs in young, overweight, females. When symptoms of intracranial pressure have an identifiable cause such as another underlying disease or medication, the condition is instead referred to as secondary IH. Treatment for IIH may include medications called carbonic anhydrase inhibitors to control the production of CSF. In some cases, weight loss may also be recommended. However, medications and/or weight loss are not effective in all cases. In severe cases that do not respond to medication and weight loss, surgery may be needed to relieve symptoms and/or preserve vision.

MalaCards based summary : Intracranial Hypertension, Idiopathic, also known as pseudotumor cerebri, is related to intracranial hypertension and papilledema, and has symptoms including neurologic symptoms An important gene associated with Intracranial Hypertension, Idiopathic is SSTR1 (Somatostatin Receptor 1), and among its related pathways/superpathways are Bile secretion and Endochondral Ossification. The drugs Doxycycline and Minocycline have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and bone, and related phenotypes are hypertension and papilledema

NINDS : 54 Pseudotumor cerebri literally means "false brain tumor." It is likely due to high pressure within the skull caused by the buildup or poor absorption of cerebrospinal fluid (CSF). The disorder is most common in women between the ages of 20 and 50. Symptoms of pseudotumor cerebri, which include headache, nausea, vomiting, and pulsating sounds within the head, closely mimic symptoms of large brain tumors.

Wikipedia : 76 Idiopathic intracranial hypertension (IIH) is a condition characterized by increased intracranial... more...

Description from OMIM: 243200

Related Diseases for Intracranial Hypertension, Idiopathic

Diseases related to Intracranial Hypertension, Idiopathic via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
# Related Disease Score Top Affiliating Genes
1 intracranial hypertension 30.3 AQP1 AQP4 SSTR1
2 papilledema 28.7 OGG1 PCLO SEMA6B
3 congenital disorder of glycosylation, type iih 12.3
4 idiopathic infantile hypercalcemia 11.3
5 inappropriate adh syndrome 10.1 AQP1 AQP4
6 central pontine myelinolysis 10.1 AQP1 AQP4
7 subependymoma 10.1 AQP1 AQP4
8 dysferlinopathy 10.0 AQP1 AQP4
9 acute hemorrhagic leukoencephalitis 10.0 AQP1 AQP4
10 neuromyelitis optica 10.0 AQP1 AQP4
11 meniere disease 9.9 AQP1 AQP4
12 diabetes insipidus, nephrogenic, autosomal 9.8 AQP1 AQP4
13 brain edema 9.7 AQP1 AQP4
14 optic nerve disease 9.6 AQP4 OPN4

Comorbidity relations with Intracranial Hypertension, Idiopathic via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential

Graphical network of the top 20 diseases related to Intracranial Hypertension, Idiopathic:



Diseases related to Intracranial Hypertension, Idiopathic

Symptoms & Phenotypes for Intracranial Hypertension, Idiopathic

Symptoms via clinical synopsis from OMIM:

57
HEENT:
idiopathic intracranial hypertension
papilledema
pseudotumor cerebri


Clinical features from OMIM:

243200

Human phenotypes related to Intracranial Hypertension, Idiopathic:

32
# Description HPO Frequency HPO Source Accession
1 hypertension 32 HP:0000822
2 papilledema 32 HP:0001085
3 increased intracranial pressure 32 HP:0002516

UMLS symptoms related to Intracranial Hypertension, Idiopathic:


neurologic symptoms

GenomeRNAi Phenotypes related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.55 IRF6
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.55 IRF6 OGG1 OPN4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.55 OGG1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.55 OGG1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.55 OPN4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.55 IRF6
7 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.55 IRF6
8 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.55 OGG1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.55 OGG1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.55 OGG1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.55 OGG1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.55 OPN4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.55 IRF6
14 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.55 IRF6
15 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.55 OPN4

MGI Mouse Phenotypes related to Intracranial Hypertension, Idiopathic:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 AQP1 AQP4 GHR OGG1 OPN4 PCLO
2 nervous system MP:0003631 9.61 AQP1 AQP4 GHR IHH OGG1 OPN4
3 vision/eye MP:0005391 9.02 AQP1 AQP4 IHH OPN4 SSTR1

Drugs & Therapeutics for Intracranial Hypertension, Idiopathic

Drugs for Intracranial Hypertension, Idiopathic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
2
Minocycline Approved, Investigational Phase 4,Phase 2 10118-90-8 5281021
3
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
4
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
5 Hormone Antagonists Phase 4
6 Hormones Phase 4
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
8 Anti-Bacterial Agents Phase 4,Phase 2,Not Applicable
9 Anti-Infective Agents Phase 4,Phase 2
10 Dermatologic Agents Phase 4
11
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
12
Acetazolamide Approved, Vet_approved Phase 2, Phase 3,Phase 3 59-66-5 1986
13
Aspirin Approved, Vet_approved Phase 2, Phase 3,Not Applicable 50-78-2 2244
14
Codeine Approved, Illicit Phase 2, Phase 3 76-57-3 5284371
15
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516
16
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
17
Naproxen Approved, Vet_approved Phase 2, Phase 3 22204-53-1 1302 156391
18 Analgesics Phase 2, Phase 3
19 Analgesics, Non-Narcotic Phase 2, Phase 3
20 Analgesics, Opioid Phase 2, Phase 3
21 Anticonvulsants Phase 2, Phase 3,Phase 3
22 Anti-Inflammatory Agents Phase 2, Phase 3
23 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
24 Antipyretics Phase 2, Phase 3
25 Antirheumatic Agents Phase 2, Phase 3
26 Antitussive Agents Phase 2, Phase 3
27 Carbonic Anhydrase Inhibitors Phase 2, Phase 3,Phase 3
28 Central Nervous System Depressants Phase 2, Phase 3
29 Chlorpheniramine, phenylpropanolamine drug combination Phase 2, Phase 3
30 Cyclooxygenase Inhibitors Phase 2, Phase 3
31 diuretics Phase 2, Phase 3,Phase 3
32 Fibrinolytic Agents Phase 2, Phase 3
33 Narcotics Phase 2, Phase 3
34 Natriuretic Agents Phase 2, Phase 3,Phase 3
35 Peripheral Nervous System Agents Phase 2, Phase 3
36 Platelet Aggregation Inhibitors Phase 2, Phase 3
37 Respiratory System Agents Phase 2, Phase 3
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
39
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
40
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
41 Micronutrients Phase 2,Not Applicable
42 Nicotinic Acids Phase 2
43 Trace Elements Phase 2,Not Applicable
44 Vitamin B Complex Phase 2
45 Vitamins Phase 2,Not Applicable
46 Antimalarials Phase 2
47 Antiparasitic Agents Phase 2
48 Antiprotozoal Agents Phase 2
49 Folate Nutraceutical Phase 2
50 Vitamin B3 Nutraceutical Phase 2

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4 Humatrope
2 Antiacne Medications Pseudotumor Cerebri Recruiting NCT02149615 Phase 4
3 ShuntCheck Accuracy in Detecting Shunt Obstruction Normal Pressure Hydrocephalus (NPH) Patients Withdrawn NCT00793416 Phase 4
4 Idiopathic Intracranial Hypertension Treatment Trial Completed NCT01003639 Phase 2, Phase 3 Acetazolamide;Placebo
5 Surgical Idiopathic Intracranial Hypertension Treatment Trial Not yet recruiting NCT03501966 Phase 3 Acetazolamide
6 Normal Pressure Hydrocephalus Treatment by Acetazolamide Terminated NCT02163330 Phase 3 Acetazolamide;sugar pill
7 Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease Unknown status NCT01834079 Phase 1, Phase 2
8 Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. Completed NCT02017444 Phase 2 AZD4017
9 BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris Completed NCT02815332 Phase 2 BPX-01 1% Minocycline Topical Gel;BPX-01 2% Minocycline Topical Gel;BPX-01 Vehicle Topical Gel
10 Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris Completed NCT01320033 Phase 2 CD2475/101 40 mg Tablets;Doxycycline 100 mg Capsules;Placebo Tablet, and Placebo Capsule
11 Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy Recruiting NCT01407809 Phase 1
12 OCT Imaging of Papilledema in Pediatric Idiopathic Intracranial Hypertension Unknown status NCT02665858 Not Applicable
13 Oxidative Stress, Low Grade Inflammation, Tissue Breakdown and Biomarkers in Cerebrospinal Fluid of A-T Unknown status NCT02285348 Not Applicable
14 The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study Completed NCT00071903
15 High/Low Dose Vit A in Diarrhea/ALRI in Severe PEM Completed NCT00388921 Not Applicable Vitamin A
16 Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension Recruiting NCT02143258 Not Applicable
17 An RCT of Bariatric Surgery vs a Community Weight Loss Programme for the Sustained Treatment of IIH Recruiting NCT02124486 Not Applicable
18 Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome Recruiting NCT02896452
19 Evaluating Raised Intracranial Pressure Using MR Elastography Recruiting NCT03096743 Not Applicable
20 Intracranial Pressure vs Percentage Body Fat Recruiting NCT03144297
21 Relaxin in Multiple Sclerosis (MS) Recruiting NCT01909492
22 Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE) Recruiting NCT03373045
23 Neurocognitive Outcome in Children Who Suffered From Idiopathic Increased Intracranial Hypertension (IIH) Active, not recruiting NCT02857335 Not Applicable
24 Analysis of Translaminar Pressure Gradient Using Noninvasive Cerebrospinal Fluid Pressure Monitoring Enrolling by invitation NCT02828891 Not Applicable
25 Multifocal Chromatic Pupilloperimetry in Patients With Pseudotumor Cerebri and Healthy Subjects. Not yet recruiting NCT03304314 Not Applicable
26 Magnetic Resonance Venography Pre- and Post-Treatment in Patients With Idiopathic Intracranial Hypertension Not yet recruiting NCT02394067
27 Venous Sinus Stenting With the River Stent in IIH Not yet recruiting NCT03556085 Not Applicable
28 Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial Not yet recruiting NCT02513914 Not Applicable
29 Axial Length and Central Corneal Thickness in Benign Intracranial Hypertension Terminated NCT02541994 Not Applicable
30 Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement Terminated NCT01863381 Not Applicable
31 Disc Edema in Patients With Chronic Kidney Disease Withdrawn NCT00769834

Search NIH Clinical Center for Intracranial Hypertension, Idiopathic

Cochrane evidence based reviews: pseudotumor cerebri

Genetic Tests for Intracranial Hypertension, Idiopathic

Anatomical Context for Intracranial Hypertension, Idiopathic

MalaCards organs/tissues related to Intracranial Hypertension, Idiopathic:

41
Brain, Eye, Bone, Ovary, Kidney, Pituitary, Thyroid

Publications for Intracranial Hypertension, Idiopathic

Articles related to Intracranial Hypertension, Idiopathic:

(show top 50) (show all 567)
# Title Authors Year
1
Pseudotumor cerebri syndrome in a patient with narcolepsy type 1. ( 29195824 )
2018
2
Pseudotumor cerebri in kaposiform lymphangiomatosis: a case report and pathogenetic hypothesis. ( 29654359 )
2018
3
Transverse venous stenting for the treatment of idiopathic intracranial hypertension, or pseudotumor cerebri. ( 29961386 )
2018
4
Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation. ( 29938337 )
2018
5
Medication-Related Pseudotumor Cerebri Syndrome. ( 27786584 )
2017
6
[Pseudotumor cerebri due to taking minocycline]. ( 28653520 )
2017
7
Pseudotumor Cerebri in Acute Promyelocytic Leukemia Patients on Intergroup Protocol 0129: Clinical Description and Recommendations forA New Diagnostic Criteria. ( 26724834 )
2016
8
Idiopathic Intracranial Hypertension (Pseudotumor Cerebri). ( 27602531 )
2016
9
Diagnostic value of the optic nerve sheath diameter in pseudotumor cerebri. ( 27168453 )
2016
10
Safe Use of Therapeutic-Dose Oral Isotretinoin in Patients With a History of Pseudotumor Cerebri. ( 26580859 )
2016
11
IgA Nephropathy in a Patient Presenting with Pseudotumor Cerebri. ( 26989531 )
2016
12
A Rare Side Effect of GnRH Agonist Treatment in Precoccious Puberty: Pseudotumor Cerebri. ( 27087351 )
2016
13
Pseudotumor Cerebri in a Child with Idiopathic Growth Hormone Insufficiency Two Months after Initiation of Recombinant Human Growth Hormone Treatment. ( 26966604 )
2016
14
Use of an Intrathecal Catheter for Analgesia, Anesthesia, and Therapy in an Obstetric Patient with Pseudotumor Cerebri Syndrome. ( 26825990 )
2016
15
Current concepts in pseudotumor cerebri. ( 26641809 )
2016
16
Pseudotumor cerebri: What We Have Learned from the Idiopathic Intracranial Hypertension Treatment Trial. ( 27128512 )
2016
17
Overweight and obesity in pediatric secondary pseudotumor cerebri syndrome. ( 25447107 )
2015
18
Pseudotumor cerebri associated with uremia and NSAIDs. ( 26022039 )
2015
19
Delayed relapse in pseudotumor cerebri due to new stenosis after transverse sinus stenting. ( 26351311 )
2015
20
Relationship Between Pattern Electroretinogram, Frequency-Domain OCT, and Automated Perimetry in Chronic Papilledema From Pseudotumor Cerebri Syndrome. ( 26047166 )
2015
21
Cerebral venous sinus stenting for pseudotumor cerebri: A review. ( 25859134 )
2015
22
Factors affecting visual loss and visual recovery in patients with pseudotumor cerebri syndrome. ( 26222108 )
2015
23
An integrated mechanism of pediatric pseudotumor cerebri syndrome: evidence of bioenergetic and hormonal regulation of cerebrospinal fluid dynamics. ( 25420176 )
2015
24
Lumboatrial shunt in a patient with Crouzon syndrome complicated by pseudotumor cerebri. ( 26021731 )
2015
25
Delayed relapse in pseudotumor cerebri due to new stenosis after transverse sinus stenting. ( 26371293 )
2015
26
An update on the pathophysiology of idiopathic intracranial hypertension alias pseudotumor cerebri. ( 25944131 )
2015
27
Endoscopic endonasal optic nerve decompression in a patient with pseudotumor cerebri. ( 25478981 )
2015
28
Venous stenting with concurrent intracranial pressure monitoring for the treatment of pseudotumor cerebri. ( 24983728 )
2014
29
A Rare presentation of neurobrucellosis in a child with Recurrent transient ischemic attacks and pseudotumor cerebri (A case report and review of literature). ( 24949055 )
2014
30
Acetazolamide for pseudotumor cerebri: evidence from the NORDIC trial. ( 24756510 )
2014
31
Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. ( 25002568 )
2014
32
Reversibility of MRI features of pseudotumor cerebri syndrome. ( 24878485 )
2014
33
Pseudotumor cerebri pathophysiology: the likely role of aldosterone. ( 25040810 )
2014
34
All-trans-retinoic acid-induced pseudotumor cerebri in acute promyelocytic leukemia. ( 25002770 )
2014
35
Pseudotumor Cerebri Pathophysiology. ( 24433163 )
2014
36
Cerebral venous sinus thrombosis and stenosis in pseudotumor cerebri syndrome. ( 24296372 )
2014
37
MR imaging findings in children with pseudotumor cerebri and comparison with healthy controls. ( 25358812 )
2014
38
Enlarged CSF spaces in pseudotumor cerebri. ( 25247982 )
2014
39
Macular thickness measurements with frequency domain-OCT for quantification of axonal loss in chronic papilledema from pseudotumor cerebri syndrome. ( 24406417 )
2014
40
Primary pseudotumor cerebri syndrome in a young obese African woman. ( 25351024 )
2014
41
Risk factors for failed transverse sinus stenting in pseudotumor cerebri patients. ( 25459247 )
2014
42
Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. ( 24821936 )
2014
43
Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. ( 24638217 )
2014
44
The pseudotumor cerebri syndrome. ( 24703535 )
2014
45
Pseudotumor cerebri: an update on treatment options. ( 25449933 )
2014
46
Severe headaches from intracranial hypertension (pseudotumor cerebri) abrogated by treatment with dextroamphetamine sulfate. ( 24779255 )
2014
47
Pseudotumor cerebri and pituitary apoplexy. ( 25421589 )
2014
48
Headache and the pseudotumor cerebri syndrome. ( 25086688 )
2014
49
High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure. ( 25180154 )
2014
50
Idiopathic intracranial hypertension: pseudotumor cerebri. ( 24512582 )
2014

Variations for Intracranial Hypertension, Idiopathic

Expression for Intracranial Hypertension, Idiopathic

Search GEO for disease gene expression data for Intracranial Hypertension, Idiopathic.

Pathways for Intracranial Hypertension, Idiopathic

Pathways related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.81 AQP1 AQP4
2 10.44 GHR IHH

GO Terms for Intracranial Hypertension, Idiopathic

Cellular components related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.1 AQP1 AQP4 GHR OPN4 SEMA6B SSTR1

Biological processes related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 renal water homeostasis GO:0003091 9.16 AQP1 AQP4
2 water transport GO:0006833 8.96 AQP1 AQP4
3 multicellular organismal water homeostasis GO:0050891 8.62 AQP1 AQP4

Molecular functions related to Intracranial Hypertension, Idiopathic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 channel activity GO:0015267 9.16 AQP1 AQP4
2 water channel activity GO:0015250 8.96 AQP1 AQP4
3 water transmembrane transporter activity GO:0005372 8.62 AQP1 AQP4

Sources for Intracranial Hypertension, Idiopathic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....